CRSP vs. PATH

Last updated Jun 6, 2026

CRSP (CRISPR Therapeutics AG) and PATH (UiPath Inc.) are both stocks. CRSP operates in Biotechnology (Healthcare), while PATH operates in Software - Infrastructure (Technology). Over the past 5 years, CRSP returned -14.47%/yr vs -31.72%/yr for PATH. At a 0.46 correlation, their price movements are largely independent.

Performance

CRSP vs. PATH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CRISPR Therapeutics AG (CRSP) and UiPath Inc. (PATH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CRSP achieves a -1.14% return, which is significantly higher than PATH's -31.42% return.

CRSP

• 1D: -8.97%
• 1M: -5.88%
• YTD: -1.14%
• 6M: -8.86%
• 1Y: 34.40%
• 3Y*: -7.06%
• 5Y*: -14.47%
• 10Y*: —

PATH

• 1D: -3.68%
• 1M: 7.05%
• YTD: -31.42%
• 6M: -39.80%
• 1Y: -15.23%
• 3Y*: -16.72%
• 5Y*: -31.72%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CRSP vs. PATH - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
CRSP CRISPR Therapeutics AG	-1.14%	33.23%	-37.12%	54.00%	-46.36%	-39.34%
PATH UiPath Inc.	-31.42%	28.95%	-48.83%	95.44%	-70.53%	-37.49%

Correlation

The correlation between CRSP and PATH is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.28
Correlation (3Y) Calculated over the trailing 3-year period	0.39
Correlation (5Y) Calculated over the trailing 5-year period	0.46
Correlation (All Time) Calculated using the full available price history since Apr 22, 2021	0.46

The correlation between CRSP and PATH shifts across timeframes, from 0.28 (1 year) to 0.46 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap CRSP : $4.98B PATH : $5.93B
EPS CRSP : -$6.24 PATH : $0.61
PS Ratio CRSP : 1.15K PATH : 3.63
PB Ratio CRSP : 2.74 PATH : 3.12
Total Revenue (TTM) CRSP : $4.10M PATH : $1.67B
Gross Profit (TTM) CRSP : -$171.17M PATH : $1.39B
EBITDA (TTM) CRSP : -$509.21M PATH : $115.98M

Return for Risk

CRSP vs. PATH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRSP

CRSP Risk / Return Rank: 58
CRSP Sharpe Ratio Rank: 60
CRSP Sortino Ratio Rank: 59
CRSP Omega Ratio Rank: 56
CRSP Calmar Ratio Rank: 60
CRSP Martin Ratio Rank: 56

PATH

PATH Risk / Return Rank: 32
PATH Sharpe Ratio Rank: 31
PATH Sortino Ratio Rank: 33
PATH Omega Ratio Rank: 32
PATH Calmar Ratio Rank: 32
PATH Martin Ratio Rank: 32

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRSP vs. PATH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for CRISPR Therapeutics AG (CRSP) and UiPath Inc. (PATH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CRSP	PATH	Difference
Sharpe ratio: Return per unit of total volatility	0.55	-0.24	+0.79
Sortino ratio: Return per unit of downside risk	1.22	0.07	+1.15
Omega ratio: Gain probability vs. loss probability	1.14	1.01	+0.13
Calmar ratio: Return relative to maximum drawdown	0.82	-0.30	+1.12
Martin ratio: Return relative to average drawdown	1.38	-0.54	+1.92
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CRSP vs. PATH - Sharpe Ratio Comparison

The current CRSP Sharpe Ratio is 0.55, which is higher than the PATH Sharpe Ratio of -0.24. The chart below compares the historical Sharpe Ratios of CRSP and PATH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CRSP	PATH	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.55	-0.24	+0.79
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.24	-0.50	+0.26
Sharpe Ratio (All Time) Calculated using the full available price history	0.23	-0.47	+0.69

Drawdowns

CRSP vs. PATH - Drawdown Comparison

The maximum CRSP drawdown since its inception was -85.11%, roughly equal to the maximum PATH drawdown of -88.98%. Use the drawdown chart below to compare losses from any high point for CRSP and PATH.

Drawdown Indicators

	CRSP	PATH	Difference
Max Drawdown Largest peak-to-trough decline	-85.11%	-88.98%	+3.87%
Max Drawdown (1Y) Largest decline over 1 year	-42.25%	-51.37%	+9.12%
Max Drawdown (3Y) Largest decline over 3 years	-64.91%	-65.10%	+0.19%
Max Drawdown (5Y) Largest decline over 5 years	-80.68%	-87.66%	+6.98%
Current Drawdown Current decline from peak	-75.32%	-86.80%	+11.48%
Average Drawdown Average peak-to-trough decline	-49.19%	-73.74%	+24.55%
Ulcer Index Depth and duration of drawdowns from previous peaks	25.06%	28.04%	-2.98%

Volatility

CRSP vs. PATH - Volatility Comparison

The current volatility for CRISPR Therapeutics AG (CRSP) is 19.12%, while UiPath Inc. (PATH) has a volatility of 20.16%. This indicates that CRSP experiences smaller price fluctuations and is considered to be less risky than PATH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CRSP	PATH	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.12%	20.16%	-1.04%
Volatility (6M) Calculated over the trailing 6-month period	43.66%	48.43%	-4.77%
Volatility (1Y) Calculated over the trailing 1-year period	62.97%	63.54%	-0.57%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	60.69%	63.64%	-2.95%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.38%	64.26%	+0.12%

Dividends

CRSP vs. PATH - Dividend Comparison

Neither CRSP nor PATH has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both CRSP and PATH in my portfolio?

CRSP and PATH have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, CRSP or PATH?

PATH has higher volatility (20.16%) compared to CRSP (19.12%). In terms of maximum drawdown, CRSP dropped -85.11% vs PATH's -88.98%.

Which has better risk-adjusted returns?

CRSP currently has the higher Sharpe Ratio (0.55 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.